Equities Analysts Issue Forecasts for Nevro Corp.’s Q1 2025 Earnings (NYSE:NVRO)

Nevro Corp. (NYSE:NVRO) – William Blair issued their Q1 2025 earnings estimates for Nevro in a note issued to investors on Tuesday, May 7th. William Blair analyst B. Vazquez forecasts that the medical equipment provider will earn ($0.92) per share for the quarter. The consensus estimate for Nevro’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Nevro’s Q4 2025 earnings at ($0.34) EPS.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.32. The company had revenue of $101.90 million during the quarter, compared to analyst estimates of $97.90 million. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.98) earnings per share.

Several other analysts have also commented on NVRO. Piper Sandler decreased their price target on shares of Nevro from $15.00 to $12.00 and set an “underweight” rating for the company in a research report on Wednesday. Citigroup decreased their price target on shares of Nevro from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, April 3rd. Royal Bank of Canada decreased their price objective on shares of Nevro from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Monday, April 15th. Canaccord Genuity Group decreased their price objective on shares of Nevro from $17.00 to $11.00 and set a “hold” rating for the company in a research report on Wednesday. Finally, Oppenheimer lowered shares of Nevro from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.00.

Nevro Stock Performance

NVRO stock opened at $10.17 on Thursday. The firm has a market cap of $373.04 million, a price-to-earnings ratio of -3.96 and a beta of 0.96. The firm has a 50-day simple moving average of $13.12 and a two-hundred day simple moving average of $16.23. Nevro has a one year low of $10.06 and a one year high of $28.89. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.94 and a current ratio of 6.37.

Hedge Funds Weigh In On Nevro

Several hedge funds and other institutional investors have recently bought and sold shares of NVRO. Armistice Capital LLC grew its stake in shares of Nevro by 46.7% during the 3rd quarter. Armistice Capital LLC now owns 3,456,000 shares of the medical equipment provider’s stock worth $66,424,000 after purchasing an additional 1,100,000 shares during the period. UBS Group AG grew its stake in shares of Nevro by 19,354.5% during the 3rd quarter. UBS Group AG now owns 903,272 shares of the medical equipment provider’s stock worth $17,361,000 after purchasing an additional 898,629 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Nevro by 69.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,048,026 shares of the medical equipment provider’s stock worth $22,554,000 after purchasing an additional 431,136 shares during the period. Norges Bank acquired a new stake in shares of Nevro during the 4th quarter worth approximately $8,498,000. Finally, Federated Hermes Inc. grew its stake in shares of Nevro by 380.1% during the 4th quarter. Federated Hermes Inc. now owns 431,153 shares of the medical equipment provider’s stock worth $9,278,000 after purchasing an additional 341,343 shares during the period. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.